Why the Epsilon (ASX:EPN) share price is soaring 16% today

After going into a trading halt on Monday, the microcap ASX cannabis company has made an announcement today.
The post Why the Epsilon (ASX:EPN) share price is soaring 16% today appeared first on The Motley Fool Australia. –

The Epsilon Healthcare Ltd (ASX:EPN) share price is rocketing today, up more than 16% to 18 cents per share.

The company entered a trading halt on Monday before the market open pending today’s announcement. Epsilon’s share price closed at 15 cents on Friday.

We take a look at the announcement from the microcap ASX cannabis share.

What did Epsilon announce?

The Epsilon share price is soaring after the company reported it has entered into a partnership with The Valens Company Inc (TSX: VLNS) for access to Epsilon’s Southport Manufacturing Facility.

Valens is involved in the production of cannabis products. Its shares currently trade on the Toronto Stock Exchange, and it has applied to list on the NASDAQ.

The partnership with Epsilon will aid Valens’ growth strategy into international GMP markets via access to Epsilon’s GMP manufacturing capability at the Southport Facility. Southport is the largest cannabis extraction facility in the Southern Hemisphere.

Epsilon has been granted a licence to use Valens IP to streamline operations at its Southport Facility. Valens will also provide personnel and support.

As part of the partnership, Valens won’t sell any medicinal cannabis in Australia or New Zealand that doesn’t come from the Southport Facility. Valens will also “fund all future operational and capital expenditure” at the facility in return for access to up to 85% of the output.

What else is moving the Epsilon share price?

Epsilon’s share price may also be getting a lift today from the company’s accompanying announcement that it has entered into a Share Sale Agreement with Cannvalate Pty Ltd to acquire AlternaMed Pty Ltd. This includes Cannvalate’s portfolio of IP covering 3 “novel cannabinoid therapeutic agents with a view to Schedule 3 medicines production”.

Epsilon will issue some 28 million shares, worth $4.3 million at 15 cents per share, to acquire AlternaMed. The acquisition remains subject to customary approvals.

Commenting on the announcements, Valens’ CEO, Tyler Robson said:

We are excited to work with the largest and most advanced cannabis manufacturing facility in the Southern Hemisphere to distribute GMP products, and look forward to advancing our product distribution capabilities through our continued partnership with Cannvalate.

Epsilon’s CEO, Jarrod White, added:

Having worked with the teams at Valens and Cannvalate over the preceding months to achieve what is a transformational partnership for Epsilon and its Southport Facility, I am excited to see the maturing of Epsilon’s core assets and business into commercial production with experienced partners from established markets.

With this long term strategic partnership now agreed, Epsilon is well placed to be a leading contract GMP manufacturer of medicinal cannabis medicines in the region.

Epsilon share price snapshot

The Epsilon share price is down 30% year-to-date. This compares to a gain of 10.5% posted by the All Ordinaries Index (ASX: XAO) in 2021.

Over the past month, Epsilon’s share price is up 16%.

The post Why the Epsilon (ASX:EPN) share price is soaring 16% today appeared first on The Motley Fool Australia.

Should you invest $1,000 in Epsilon right now?

Before you consider Epsilon, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Epsilon wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

3 top quality ETFs for ASX investors

Dicker Data (ASX:DDR) share price continues to slide, down 21% since late August
Why the IOUpay (ASX:IOU) share price is leaping higher
Top brokers name 3 ASX shares to sell today

Which ASX 300 shares are making headlines on Thursday?

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Valens GroWorks Corp. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Valens GroWorks. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!